$ACT Recent Headlines DEA restricts narcotic pain-drug

New Post Public Reply Private Reply Replies (0) Message Board

Sep 9, 2014 at 11:33 AM

$ACT Recent Headlines

DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis raises guidance as earnings top views 8:11 a.m. Aug. 5, 2014 - MarketWatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Leon Cooperman talks up Citi, Thermo Fisher 11:20 a.m. July 16, 2014 - Sue Chang
Leon Cooperman likes Thermo Fisher, Citi, Actavis 11:06 a.m. July 16, 2014 - Sue Chang
10 biggest S&P 500 winners and losers for 2014 10:44 a.m. July 1, 2014 - Philip van Doorn
Affiliated Managers Group to join S&P 500 5:33 p.m. June 24, 2014 - Wallace Witkowski
10 best-performing S&P 500 stocks of 2014 2:38 p.m. June 2, 2014 - Philip van Doorn
Pfizer's plan to relocate after merger deal draws lawmakers' fire 11:30 a.m. May 9, 2014 - Russ Britt
Corner drug store may move overseas to save on taxes 6:31 a.m. April 16, 2014 - Al Lewis
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
Actavis acquires Silom Medical for $100 million 10:19 a.m. April 1, 2014 - MarketWatch.com
The 10 most overbought stocks in the S&P 500 index 12:19 p.m. March 25, 2014 - The Trading Deck
UK drug rejection, patent concerns take a bite out of Celgene shares 1:33 p.m. March 14, 2014 - Russ Britt
Mylan to start selling generic Celebrex in May 7:23 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - Russ Britt
Staples awash in red; eBay up as Icahn posts new letter 5:09 p.m. March 6, 2014 - Sue Chang
Icahn Enterprises reports profit up 144% in 2013 11:23 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 12:12 p.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 5:46 p.m. Feb. 24, 2014 - Victor Reklaitis

Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog 5:20 p.m. Sept. 8, 2014 - Zacks.com
Synergy Pharmaceuticals Could Be A Diamond In The Rough 12:30 p.m. Sept. 8, 2014 - Seeking Alpha
Pfizer: You Won't Fool Me Twice 1:28 a.m. Sept. 7, 2014 - Seeking Alpha
IBD 50 Showing Little Distress, But Few Big Winners 5:45 p.m. Sept. 5, 2014 - Investors Business Daily
Orexigen Gets Weight Loss Drug Patent, May See Runup Into Approval Decision 11:46 a.m. Sept. 5, 2014 - Seeking Alpha
The Top Net Buys Of The Hedge Fund Gurus 5:59 p.m. Sept. 4, 2014 - GuruFocus.com
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog 4:30 p.m. Sept. 4, 2014 - Zacks.com
3 Stocks Advancing The Health Care Sector 1:03 p.m. Sept. 4, 2014 - TheStreet.com
Sterne Agee Raises Actavis plc Estimates, Price Target 10:58 a.m. Sept. 4, 2014 - benzinga.com
Shares Of Actavis Are Up ~1.5% On FDA Approval 9:55 a.m. Sept. 4, 2014 - benzinga.com
UPDATE: Morgan Stanley Reiterates On Actavis plc As M&A Could Offer Additional Upside 9:00 a.m. Sept. 4, 2014 - benzinga.com
Actavis's Watson Labs ANDA Approved By FDA 8:41 a.m. Sept. 4, 2014 - benzinga.com
New Lifetime High For Actavis (ACT) 9:46 a.m. Sept. 3, 2014 - TheStreet.com
FDA accepts eluxadoline NDA 2:02 p.m. Sept. 2, 2014 - Seeking Alpha
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog 4:40 p.m. Aug. 28, 2014 - Zacks.com
Top 4 BlackRock Funds to Buy Now 6:34 a.m. Aug. 28, 2014 - InvestorPlace.com
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2014 Update 10:34 a.m. Aug. 23, 2014 - Seeking Alpha
Supernus' Trokendi XR Faces Generic Threat from Actavis - Analyst Blog 4:55 p.m. Aug. 22, 2014 - Zacks.com
Clampdown on Popular Painkillers 12:18 p.m. Aug. 22, 2014 - The Wall Street Journal Interactive Edition
Wall Street Breakfast: Restrictions Imposed On Citigroup's Hedge Fund Sales 6:33 a.m. Aug. 22, 2014 - Seeking Alpha

Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte 8:55 a.m. Today - PR Newswire - PRF
Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product 8:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 9:20 a.m. Sept. 2, 2014 - PR Newswire - PRF
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 9:10 a.m. Aug. 29, 2014 - PR Newswire - PRF
Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 4:05 p.m. Aug. 26, 2014 - PR Newswire - PRF
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 11:15 a.m. Aug. 19, 2014 - PR Newswire - PRF
Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI) 7:24 a.m. Aug. 19, 2014 - PR Newswire - PRF
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42 7:00 a.m. Aug. 5, 2014 - PR Newswire - PRF
Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert™ IUD 4:30 p.m. July 21, 2014 - PR Newswire - PRF
Drug Application Submission, Merger Agreement, Launch of Newly Approved Drug, and Acquisition - Analyst Notes on Actavis, Salix, Mylan, Zoetis and Hospira 5:10 a.m. July 14, 2014 - PR Newswire - PRF
Actavis Confirms Generic Diclegis® Patent Challenge 4:25 p.m. July 11, 2014 - PR Newswire - PRF
Actavis Confirms Generic Ampyra® Patent Challenge 4:05 p.m. July 8, 2014 - PR Newswire - PRF
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma 5:30 a.m. July 4, 2014 - PR Newswire - PRF
Impax Acquires Two Products from Actavis 4:05 p.m. July 2, 2014 - PR Newswire - PRF
Actavis Completes Acquisition of Furiex Pharmaceuticals 8:46 a.m. July 2, 2014 - PR Newswire - PRF
Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition 8:00 a.m. July 2, 2014 - PR Newswire - PRF
Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger 3:15 p.m. July 1, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YeePay's B2B Payment Innovations Target Airlines' Pain Points

A New Takeoff for Airline B2B Payments Dusting off the cobwebs of traditional payment processes, YeePay has been busy at the 2026 IATA WFS & WPS, held on the glitzy floor of the Galaxy International Convention Center in Macau from October 28 to 29. They're not just chatting about travel; they're rolling out a novel way to tackle the headaches in airline B2B order...

PRG Projects' London Studio Elevates Live Entertainment

A New Stage for Creativity in London When the curtain rises on a fresh idea, it's often the unknowns that make or break a production. Now, with PRG Projects unveiling their spanking new Project Studio in London, the tech and creative worlds might just bridge their gap tighter than a stage curtain before showtime. London Welcomes PRG's Innovative Hub This isn't just...

Monetary Metals' Bold $38M Gold Bond: A Strategic Leap

A Golden Opportunity in Uncertain Times Monetary Metals just pulled a rabbit outta the hat with this $38 million gold bond. That’s tripling the size from their 2024 offering. Normally, I'm skeptical about flashy bond numbers, but there's a glint of genius here. In a world teetering on the brink of financial chaos, investors are itching for something solid. And gold?...

Aosom Unveils Its Boldest Black Friday Extravaganza

Black Friday Heat Kicks Off Early at Aosom All the seasoned shoppers out there smell a deal from a mile away, and Aosom isn't taking any chances by launching their Black Friday bash smack dab on November 2nd. This isn’t just any sale, it’s shaping up to be their most gigantic festival of discounts yet. Across Europe and North America, folks are rubbing their hands...

AI-Powered Bank Set to Transform Bahrain's Financial Landscape

A Fresh Approach to Banking in Bahrain The stuff that's stirring the pot in Bahrain’s financial sector right now? This big ol' partnership between Mumtalakat, the Kingdom's sovereign wealth fund, and ARP Group. They're on a mission to launch an AI-native wholesale bank smack dab in Bahrain. But here’s the kicker – they’ve got the green light, in principle at...

UPM-Kymmene Finalizes Demerger: WISA Group to Nasdaq

UPM-Kymmene Shakes Things Up Here's the meat and potatoes: UPM-Kymmene Corporation is going through a big change. They've decided to cut a part of themselves off and send it out into the world. This partial demerger has been registered, and now WISA Group Plc is stepping out from UPM's shadow. Where to? They're headed for the big league, getting listed on Nasdaq Helsinki....

Ericsson Executes Aggressive $54M Share Buyback

Digging Into Ericsson's Latest Buyback Getting straight to brass tacks, the recent maneuver by Ericsson (SE0000108656)—snapping back 500,000 shares from October 26 to October 30, 2026—raised more than a few eyebrows in the financial alleys. Shelling out SEK 54.46 million in less than a week is no small potatoes, but it’s all part of a grander financial ballet...

Curaleaf Takes Stake in NJ's Boone Town Dispensary

Curaleaf's Bold Move in the Garden State Curaleaf Holdings, Inc. is doubling down on its cannabis bet in New Jersey. The acquisition of an equity stake in Boone Town Provisions, located at 677 Myrtle Ave., Boonton, NJ, boosts Curaleaf’s dispensary count to four in the state. The company's not just wandering on the map; it's pinpointing high-performing locations to...

ELEGOO Slashes Prices up to 54% for 2026 Holiday Deals

ELEGOO's 2026 Holiday Strategy: Deep Discounts Welcome to the world of sharp deals and crafty creations as ELEGOO kicks off its Black Friday and Cyber Monday extravaganza. This time, they're slashing prices by up to 54% on their impressive lineup of 3D printers and captivating accessories. Yeah, it's that time of year when wallets might take a hit, but for a good reason....

XPENG Gears Up for Q3 2026 Results Amid AI Advancements

XPENG's Upcoming Financial Disclosure XPENG Inc., a name that rings bells in the smart mobility world, is setting the stage for its third quarter 2026 financial results on November 16. Someone with a sharp enough gut could probably see it a mile away—these numbers might just be the ticket for a ride amid XPENG's high wire AI advancements. But let's not kid ourselves;...